Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome
Authors: Stephan Moll
Journal: Annals of Internal Medicine (2020)

Letters7 April 2020Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid SyndromeStephan Moll, MDStephan Moll, MDUniversity of North Carolina School of Medicine, Chapel Hill, North Carolina (S.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-0053 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:A bias influencing the finding that more thrombotic events occurred in the rivaroxaban group than in the VKA group may have been introduced in Ordi-Ros and colleagues' study (1). This study may have favored enrollment of patients who tended to respond well to VKAs. It would be important to know how long patients had been receiving anticoagulants for their previous thrombotic events before they were enrolled in this study and how many of these patients had previously been treated with a VKA or a direct oral anticoagulant. Given the enrollment criteria, I suspect that the anticoagulant used ...References1. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome. A randomized noninferiority trial. Ann Intern Med. 2019;171:685-94. [PMID: 31610549] LinkGoogle Scholar2. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-8. [PMID: 13679527] CrossrefMedlineGoogle Scholar3. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848-53. [PMID: 15869575] CrossrefMedlineGoogle Scholar4. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132:1365-71. [PMID: 30002145] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of North Carolina School of Medicine, Chapel Hill, North Carolina (S.M.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-0053. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome Josep Ordi-Ros , Luis Sáez-Comet , Mercedes Pérez-Conesa , Xavier Vidal , Antoni Riera-Mestre , Antoni Castro-Salomó , Jordi Cuquet-Pedragosa , Vera Ortiz-Santamaria , Montserrat Mauri-Plana , Cristina Solé , and Josefina Cortés-Hernández Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome Derek Leong and Peter E. Wu Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome Josefina Cortés-Hernández Metrics Cited byUnexplained arterial thrombosis: approach to diagnosis and treatmentRivaroxaban Versus Vitamin K Antagonist in Antiphospholipid SyndromeJosefina Cortés-Hernández, MD, PhD 7 April 2020Volume 172, Issue 7Page: 510KeywordsAnticoagulantsAntiphospholipid syndromeConflicts of interestDisclosureThrombosisVitamin K ePublished: 7 April 2020 Issue Published: 7 April 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...